Year: 2022

news_6

ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

Daiichi Sankyo and AstraZeneca’s ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients...